Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy

MLA

Jorge M. Ramos Perez, et al. “Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy.” Blood, vol. 140, Nov. 2022, pp. 9039–40. EBSCOhost, https://doi.org/10.1182/blood-2022-170867.

APA

Jorge M. Ramos Perez, Jose Tinajero, Dat Ngo, Jianying Zhang, Paul B. Koller, Vaibhav Agrawal, Hoda Pourhassan, Monzr M. Al Malki, Amandeep Salhotra, Haris Ali, Ahmed Aribi, Karamjeet S. Sandhu, Shukaib Arslan, Salman Otoukesh, Idoroenyi Amanam, Andrew S. Artz, Pamela S. Becker, Forrest M. Stewart, Eileen P. Smith, … Brian J Ball. (2022). Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy. Blood, 140, 9039–9040. https://doi.org/10.1182/blood-2022-170867

Chicago

Jorge M. Ramos Perez, Jose Tinajero, Dat Ngo, Jianying Zhang, Paul B. Koller, Vaibhav Agrawal, Hoda Pourhassan, et al. 2022. “Evaluation of 5-Day Vs. 10-Day Decitabine in Combination with Venetoclax in Newly Diagnosed AML Patients Ineligible for Induction Chemotherapy.” Blood 140 (November): 9039–40. doi:10.1182/blood-2022-170867.